Photo taken from
Giannis Mountzios/X
Jun 2, 2024, 11:16
Giannis Mountzios: Lorlatinib in ALK positive NSCLC sets a new benchmark in Precision Oncology
Giannis Mountzios, Medical Oncologist at the Department of Medical Oncology in the Air Force General Hospital, Athens, recently shared on X:
“For the 1st time in the history of Thoracic Oncology a molecular agent confers a median PFS exceeding 5 years in metastatic disease! Lorlatinib in ALK-positive NSCLC with the CROWN study sets a new benchmark in Precision Oncology!
Deserve to celebrate!”
Source: Giannis Mountzios/X
